Local 12: Diabetes study focuses on how long blood sugar control can be maintained
The University of Cincinnati's Robert Cohen, MD, spoke with Local 12 about the GRADE study.
"This was a type two diabetes study, and whereas most studies are looking at how good the blood sugar control can be, this study was focused on how long the blood sugar control can be maintained,” said Cohen, a professor in UC's College of Medicine and UC Health endocrinologist.
Maintaining blood sugar control near normal levels can lower the risk of further complications like heart and kidney disease and vision problems for people with diabetes, Cohen said.
The years-long study found medications now known as Ozempic or Mounjaro were some of the best at maintaining long-term blood sugar control.
“That and insulin itself really did the best job of preserving glycemic blood sugar control,” Cohen said.
As the research continues, Cohen said the team will move beyond drugs that bring down blood sugar levels to evaluate drugs that preserve insulin-producing cells.
Watch or read the Local 12 story.
Featured photo at top of a semaglutide injection pen. Photo/aprott/iStock.
Related Stories
Is a colonoscopy painful?
May 13, 2026
The University of Cincinnati's Susan Kais, MD, assistant professor of clinical medicine in the Division of Gastroenterology and Hepatology in the College of Medicine and UC Health gastroenterologist, recently appeared on the ARC Cincinnati morning program on Local 12/WKRC-TV to answer common questions from viewers about colonoscopies and to dispel myths.
Telescope captures information about lonely Jupiter-like gas giant
May 13, 2026
Science outlets highlight a University of Cincinnati student's collaborative discoveries about an exoplanet 901 light years away.
UC achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy
May 13, 2026
Researchers at the University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center have been confirmed as the first in the world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment. The findings were published in Surgical Neurology International and recently featured in The Cancer Letter.